From the Journals

RA-ILD: Tracking Function and CT

Conventional monitoring markers do not change before deaths in this predominantly mild cohort.

Share

  • 1

    105 RA-ILD patients were studied over 24 months.

  • 2

    8% mortality rate recorded, largely unrelated to pulmonary decline.

  • 3

    Majority exhibited mild RA-ILD with 80% having pulmonary fibrosis.

  • 4

    FVC remained stable at 76% across the study.

  • 5

    12% improved, 69% stable, and 19% worsened at 24 months in imaging assessments.

  • 6

    Challenges conventional views on ILD mortality patterns.

  • 7

    Study's limitations include sample size and follow-up issues due to COVID-19.

Original Source(s)

RA-ILD: Tracking Function and CT

  • by Kathryn Wighton

  • March 6, 2026

Related Content

Dry Eye Across Autoimmune Diseases

The nationwide analysis found the highest rates of dry eye disease among patients with Sjögren’s syndrome.

​​​​​​​PsA Treatment Options Expand

Phase 3 POETYK trial results support FDA approval of deucravacitinib for adults with active PsA.

Anti-CD146 Linked to Silica in Systemic Sclerosis

Comparative analysis across exposed workers, cancer controls, and healthy donors supports specificity.